Oncternal Therapeutics (NASDAQ:ONCT) Earns Hold Rating from Analysts at StockNews.com

Analysts at StockNews.com initiated coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a report released on Monday. The brokerage set a “hold” rating on the stock.

Oncternal Therapeutics Price Performance

Shares of Oncternal Therapeutics stock opened at $0.53 on Monday. Oncternal Therapeutics has a 1-year low of $0.53 and a 1-year high of $10.27. The company has a market capitalization of $1.56 million, a P/E ratio of -0.05 and a beta of 1.18. The business’s fifty day moving average price is $0.53 and its two-hundred day moving average price is $1.32.

About Oncternal Therapeutics

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.